TD Asset Management Inc trimmed its position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 34.2% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,578,333 shares of the company’s stock after selling 1,341,743 shares during the quarter. TD Asset Management Inc’s holdings in AbbVie were worth $648,812,000 at the end of the most recent reporting period.
A number of other large investors also recently modified their holdings of ABBV. Boomfish Wealth Group LLC grew its position in AbbVie by 5.3% in the 2nd quarter. Boomfish Wealth Group LLC now owns 1,443 shares of the company’s stock valued at $363,000 after purchasing an additional 72 shares during the period. Strive Financial Group LLC raised its holdings in AbbVie by 192.1% during the second quarter. Strive Financial Group LLC now owns 2,182 shares of the company’s stock worth $549,000 after buying an additional 1,435 shares during the last quarter. Capital City Trust Co. FL raised its holdings in AbbVie by 0.5% during the second quarter. Capital City Trust Co. FL now owns 34,427 shares of the company’s stock worth $8,663,000 after buying an additional 164 shares during the last quarter. Atlantic Family Wealth LLC lifted its stake in shares of AbbVie by 19.6% in the second quarter. Atlantic Family Wealth LLC now owns 1,643 shares of the company’s stock valued at $413,000 after buying an additional 269 shares in the last quarter. Finally, Chilton Capital Management LLC lifted its stake in shares of AbbVie by 1.6% in the second quarter. Chilton Capital Management LLC now owns 13,608 shares of the company’s stock valued at $3,424,000 after buying an additional 213 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors.
Key AbbVie News
Here are the key news stories impacting AbbVie this week:
- Positive Sentiment: New lung-cancer data supports AbbVie’s long-term growth strategy. At the 2026 World Conference on Lung Cancer, AbbVie presented clinical, translational and real-world data for investigational programs including ABBV-1480, telisotuzumab adizutecan and ABBV-706 across non-small cell and small cell lung cancer. The updates highlight potential future oncology revenue sources beyond the company’s established immunology portfolio. AbbVie WCLC 2026 announcement
- Positive Sentiment: AbbVie is broadening its aesthetics pipeline. The company has initiated a Phase 2 study evaluating a treatment for forehead lines, adding another potential product to its aesthetics franchise and reinforcing efforts to diversify growth. AbbVie aesthetics pipeline update
- Neutral Sentiment: AbbVie’s relatively low market correlation reflects its defensive pharmaceutical revenue base. Investor performance is driven more by product demand, reimbursement and payer dynamics than by broad equity-market movements. This may help explain the stock’s resilience, but the article does not identify a new earnings catalyst. What Moves AbbVie Stock
- Neutral Sentiment: AbbVie recently reported quarterly EPS and revenue above consensus, with revenue rising 10.2% year over year, and guided to third-quarter EPS of $3.84–$3.88. Analysts’ average price target of $275.73 remains above the current trading level, although the stock’s elevated valuation raises expectations. AbbVie stock and earnings information
- Negative Sentiment: An early end to a long-term emraclidine schizophrenia study introduces uncertainty. Investors may question the implications for AbbVie’s neuroscience pipeline and the program’s development prospects until the company provides additional details. AbbVie emraclidine study update
- Negative Sentiment: An executive vice president sold approximately $8.18 million of ABBV shares, reducing his position by about 30.5%. The sale may weigh modestly on sentiment, although insider transactions can reflect personal financial planning rather than a change in business outlook. AbbVie insider sale
AbbVie Trading Up 1.4%
AbbVie (NYSE:ABBV – Get Free Report) last announced its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The firm had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. During the same quarter in the prior year, the company earned $2.97 EPS. The business’s revenue for the quarter was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Analysts predict that AbbVie Inc. will post 14.06 EPS for the current fiscal year.
AbbVie Dividend Announcement
The business also recently declared a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were given a dividend of $1.73 per share. The ex-dividend date was Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.6%. AbbVie’s dividend payout ratio is presently 195.48%.
Insiders Place Their Bets
In related news, EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares in the company, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.06% of the company’s stock.
Wall Street Analyst Weigh In
Several research firms have recently commented on ABBV. Piper Sandler boosted their target price on shares of AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a research report on Thursday. BMO Capital Markets raised their price target on shares of AbbVie from $258.00 to $300.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. JPMorgan Chase & Co. raised their price target on shares of AbbVie from $260.00 to $280.00 and gave the company an “overweight” rating in a research report on Thursday, July 9th. Cantor Fitzgerald lifted their price target on AbbVie from $265.00 to $285.00 and gave the company an “overweight” rating in a research note on Monday, August 3rd. Finally, Wells Fargo & Company boosted their price objective on AbbVie from $295.00 to $300.00 and gave the stock an “overweight” rating in a report on Monday, August 17th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $275.95.
Read Our Latest Stock Analysis on AbbVie
AbbVie Company Profile
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
Featured Articles
- Five stocks we like better than AbbVie
- 2 Biotech Stocks Shaping Up for Major Breakouts
- 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs
- 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run
- Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit?
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
